You've likely heard a million different warnings about the changes taking place in America's financial system right now... How the White House plans to take the dollar fully digital???

Norman Greenberg Biography and Net Worth

Insider of Atreca

Mr. Norman Greenberg is the Insider of Atreca.

What is Norman Michael Greenberg's net worth?: The estimated net worth of Norman Michael Greenberg is at least $177.14 as of March 17th, 2021. Mr. Greenberg owns 2,084 shares of Atreca stock worth more than $177 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Greenberg may own. Learn More about Norman Michael Greenberg's net worth.
How do I contact Norman Michael Greenberg?: The corporate mailing address for Mr. Greenberg and other Atreca executives is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. Atreca can also be reached via phone at (650) 595-2595 and via email at [email protected]. Learn More on Norman Michael Greenberg's contact information.
Has Norman Michael Greenberg been buying or selling shares of Atreca?: Norman Michael Greenberg has not been actively trading shares of Atreca in the last ninety days. Most recently, Norman Michael Greenberg sold 5,000 shares of the business's stock in a transaction on Wednesday, March 17th. The shares were sold at an average price of $16.73, for a transaction totalling $83,650.00. Following the completion of the sale, the insider now directly owns 2,084 shares of the company's stock, valued at $34,865.32. Learn More on Norman Michael Greenberg's trading history.
Who are Atreca's active insiders?: Atreca's insider roster includes Norman Greenberg (Insider), William Robinson (Director), and Tito Serafini (Insider). Learn More on Atreca's active insiders.
Are insiders buying or selling shares of Atreca?: In the last twelve months, insiders at the sold shares 3 times. They sold a total of 284,302 shares worth more than $118,980.45. The most recent insider tranaction occured on October, 19th when Major Shareholder Bros. Advisors Lp Baker sold 274,739 shares worth more than $109,895.60. Insiders at Atreca own 11.3% of the company. Learn More about insider trades at Atreca.
Information on this page was last updated on 10/19/2023.

Norman Michael Greenberg Insider Trading History at Atreca

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2021	Sell	5,000	$16.73	$83,650.00	2,084
1/19/2021	Sell	5,000	$15.21	$76,050.00	5,000
12/17/2020	Sell	5,000	$16.61	$83,050.00	5,000
11/27/2020	Sell	3,175	$15.34	$48,704.50	3,175
11/10/2020	Sell	4,500	$15.10	$67,950.00	4,500
10/19/2020	Sell	500	$15.12	$7,560.00	500
7/1/2020	Sell	10,272	$21.83	$224,237.76	10,272
6/1/2020	Sell	15,000	$18.38	$275,700.00	15,000
5/7/2020	Sell	5,000	$18.00	$90,000.00	5,000
5/1/2020	Sell	10,000	$15.03	$150,300.00	10,000
4/14/2020	Sell	5,000	$18.00	$90,000.00	5,000
4/8/2020	Sell	8,000	$15.01	$120,080.00	8,000
4/1/2020	Sell	2,000	$15.21	$30,420.00	2,000
2/3/2020	Sell	15,000	$19.65	$294,750.00	15,000
1/24/2020	Sell	5,000	$18.47	$92,350.00	5,000

Norman Michael Greenberg Buying and Selling Activity at Atreca

Atreca Company Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Today's Range

Now: $0.09

$0.08

$0.09

50 Day Range

MA: $0.16

$0.06

$0.32

2 Week Range

Now: $0.09

$0.05

$1.26

Volume

85,050 shs

Average Volume

6,660,004 shs

Market Capitalization

$3.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Fed launches fourth dollar overhaul

From Stansberry Research | Ad